|
|
|
Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time.
Sign up now!
Already registered? Please sign in.
Alternatively, please use our pay-per-view service. |
|
|
 |
Industry Events |
 |
INTERPHEX 2020
15-17 July 2020, Javits Center NYC
More info >> |
|
 |
News and Press Releases |
 |
TAGRISSOTM (osimertinib) DEMONSTRATED UNPRECEDENTED DISEASE-FREE SURVIVAL IN THE ADJUVANT TREATMENT OF STAGE IB-IIIA COMPLETELY RESECTED PATIENTS WITH EGFR MUTATION
Detailed results from the Phase III ADAURA trial showed AstraZeneca’s
Tagrisso (osimertinib) demonstrated a statistically significant and
clinically meaningful improvement in disease-free survival (DFS) in the
adjuvant treatment of patients with early-stage (IB, II and IIIA)
epidermal growth factor receptor-mutated (EGFRm) non-small cell lung
cancer (NSCLC) after complete tumour resection with curative intent.
More info >> |
|
|
